Cargando…
Human Positive Coactivator 4 Affects the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma via the mTOR/P70s6k Signaling Pathway
INTRODUCTION: Pancreatic cancer is one of the deadliest cancers in the world, and pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all cases. Human positive coactivator 4 (PC4) is a transcriptional coactivator that has been associated with the development and progression of several tumors...
Autores principales: | Su, Xingxing, Yang, Yishi, Ma, Le, Luo, Peng, Shen, Kaicheng, Dai, Haisu, Jiang, Yan, Shuai, Ling, Liu, Zhipeng, You, Jinshan, Min, Ke, Shi, Chunmeng, Chen, Zhiyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705283/ https://www.ncbi.nlm.nih.gov/pubmed/33273827 http://dx.doi.org/10.2147/OTT.S284219 |
Ejemplares similares
-
PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cancer
por: Yang, Yishi, et al.
Publicado: (2021) -
PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells
por: Dai, Haisu, et al.
Publicado: (2019) -
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016) -
The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism
por: Zhu, Hengyue, et al.
Publicado: (2021) -
VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAMTOR2-mediated mTOR activation
por: Xu, Jichuan, et al.
Publicado: (2023)